Citation: Wf. Mangel et al., A new form of antiviral combination therapy predicted to prevent resistance from arising, and a model system to test it, CURR MED CH, 8(8), 2001, pp. 933-939
Citation: Rw. Sidwell et al., Influence of virus strain, challenge dose, and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201, ANTIVIR RES, 51(3), 2001, pp. 179-187
Citation: Df. Smee et al., Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities, ANTIM AG CH, 45(3), 2001, pp. 743-748
Citation: Rw. Sidwell et al., In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RWJ-270201, ANTIM AG CH, 45(3), 2001, pp. 749-757
Authors:
Baniecki, ML
McGrath, WJ
McWhirter, SM
Li, C
Toledo, DL
Pellicena, P
Barnard, DL
Thorn, KS
Mangel, WF
Citation: Ml. Baniecki et al., Interaction of the human adenovirus proteinase with its 11-amino acid cofactor pVIc, BIOCHEM, 40(41), 2001, pp. 12349-12356
Authors:
Barnard, DL
Sidwell, RW
Xiao, W
Player, MR
Adah, SA
Torrence, PF
Citation: Dl. Barnard et al., 2-5A-DNA conjugate inhibition of respiratory syncytial virus replication: effects of oligonucleotide structure modifications and RNA target site selection, ANTIVIR RES, 41(3), 1999, pp. 119-134